Compare Regeneron Pharmaceuticals Inc (REGN) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $744.35 (market cap $76.14B), while Direxion Daily S&P 500 Bull 3X Shares trades at $296.67 (market cap $7.36B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10.3× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| REGN | SPXL | |
|---|---|---|
Market Cap | $76.14B | $7.36B |
Volume | 500,239 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $301.38 |
52-Week Low | $557.73 | $170.20 |
Typical Hold Time | 107 Days | 32 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SPXL trades at $296.84, down 0.79% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains neutral oscillator signals while approaching key resistance at $299. Recent market sentiment reflects mixed outlooks for S&P 500 performance amid earnings growth concerns and seasonal patterns.
The leveraged ETF's performance remains tied to S&P 500 movements, with Wall Street projecting potential upside but facing headwinds from expected earnings growth slowdown. Key risks include market concentration in top holdings and geopolitical uncertainties affecting broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
